Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculous tenosynovitis and bursitis: imaging findings in 21 cases.

Radiology·1996
Same author

Recombinant mitotoxin basic fibroblast growth factor-saporin reduces venous anastomotic intimal hyperplasia in the arteriovenous graft.

Circulation·1996
Same author

Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·1996
Same author

Differences in cholinergic responses from outer hair cells of rat and guinea pig.

Hearing research·1996
Same author

Pharmacokinetics of retinoids in women after meal consumption or vitamin A supplementation.

Journal of clinical pharmacology·1996
Same author

Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

The Journal of biological chemistry·1996

Related Experiment Video

Updated: May 12, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Lenalidomide in multiple myeloma-a practice guideline.

C Chen1, F Baldassarre, S Kanjeekal

  • 1Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON.

Current Oncology (Toronto, Ont.)
|April 6, 2013
PubMed
Summary

Lenalidomide, an immunomodulatory drug, is recommended for multiple myeloma treatment. Guidelines cover its use in various disease stages and toxicity management, improving patient outcomes.

Keywords:
Lenalidomideimidmultiple myelomapractice guideline

Related Experiment Videos

Last Updated: May 12, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Lenalidomide is a promising immunomodulatory agent for multiple myeloma.
  • Guidelines are needed for its use in relapsed, refractory, and newly diagnosed multiple myeloma.
  • Management strategies for lenalidomide-related toxicities are essential.

Purpose of the Study:

  • To develop a provincial guideline for lenalidomide use in multiple myeloma.
  • To address lenalidomide's application in diverse patient groups and treatment settings.
  • To provide recommendations for managing treatment-related toxicities.

Main Methods:

  • Systematic literature search of Medline, Embase, and Cochrane Library.
  • Inclusion of meeting abstracts and relevant organizational websites.
  • Development of recommendations based on published evidence and clinical expertise.

Main Results:

  • Evidence from published studies informed the guideline development.
  • Clinical expertise from working groups and disease site groups was utilized.
  • Recommendations were formulated for lenalidomide use and toxicity management.

Conclusions:

  • Lenalidomide combined with dexamethasone is recommended for untreated and treated multiple myeloma.
  • Guidelines address the management of cytopenias, venous thromboembolism, and secondary malignancies.
  • The guideline supports optimal lenalidomide utilization in multiple myeloma care.